Distal Arthrogryposis Type 2A
Freeman-Sheldon Syndrome - Distal Arthrogryposis Type 2A
Diagnosis
Indications for Testing
- Clinical presentation compatible with syndrome
Laboratory Testing
- Freeman-Sheldon syndrome (MYH3) sequencing
- MYH3 mutation detected – predictive of FSS
- No mutation detected – risk for FSS reduced but not eliminated
Differential Diagnosis
- Sheldon-Hall syndrome
- Distal arthrogryposis type 1
- Trismus-pseudocamptodactyly syndrome
- Congenital contractual arachnodactyly (Beals-Hecht syndrome)
Clinical Background
Freeman-Sheldon syndrome (FSS) is a rare form of the multiple congenital contracture (arthrogryposis) syndromes. It is characterized by facial muscle contractures (“whistler appearance”), skeletal and joint abnormalities.
Epidemiology
- Incidence – rare (~100 cases reported to date)
- Prevalence – appears to be similar across populations but most reported individuals are of European ancestry
- Age – usually diagnosed in childhood; initial diagnosis rare >30 years
- Sex – M:F, equal
Inheritance
- Autosomal dominant inheritance – ~70% of cases represent new mutations
- Mutations in MYH3 gene – 93% of cases
- Two common missense mutations, c.2014C>T (p.R672C) and c.2015G>A (p.R672H), occur in exon 17 of MYH3 – 72% of FSS cases
- No other FSS-associated genes identified to date
Pathophysiology
- MYH3 mutations affect structure of myosin head near the ATP-binding sites
- Disrupt the normal function of myosin in muscle contraction
Clinical Presentation
- Craniofacial – facial dysmorphism, strabismus, dental crowding, hearing loss, facial muscle contractures
- Musculoskeletal – scoliosis, restricted cervical flexion, joint contractures of hands, fingers, hips, knees, ankles, feet, and toes
- Genitalia – cryptorchidism, inguinal hernia
- Life threatening respiratory complications common in perinatal and neonatal period
Indications for Laboratory Testing
- Tests generally appear in the order most useful for common clinical situations
- Click on number for test-specific information in the ARUP Laboratory Test Directory
| Test Name and Number |
Recommended Use |
Limitations |
Follow Up |
| Freeman-Sheldon Syndrome (MYH3) Sequencing Exon 17 2002662 Method: Polymerase Chain Reaction/Sequencing |
Confirm clinical diagnosis of FSS Only detects exon 17 mutations |
Rare diagnostic errors can occur due to primer site mutations |
|
General References
National Organization for Rare Disorders. National Organization for Rare Disorders, ed. NORD Guide to Rare Disorders, 3, illustrated ed. Philadelphia: Lippincott Williams & Wilkins, 2003. pp. 714-715.
References from the ARUP Institute for Clinical and Experimental Pathology®